US · CLGN
CollPlant Biotechnologies Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Rehovot 7670104
- Website
- collplant.com
Price · as of 2024-12-31
$0.41
Market cap 7.18M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $48.81 | +11,787.48% |
| Intrinsic Value(DCF) | $1.34 | +226.35% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $120.53 | +29,254.6% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $7.00 | $73.93 | $0.00 | $0.00 | $0.00 |
| 2018 | $6.00 | $302.32 | $0.00 | $0.00 | $0.00 |
| 2019 | $12.10 | $67.01 | $0.00 | $0.00 | $92.30 |
| 2020 | $14.16 | $68.95 | $14,790.59 | $0.00 | $0.00 |
| 2021 | $9.00 | $315.96 | $180,614.54 | $4.64 | $3.71 |
| 2022 | $8.95 | $1,280.49 | $1.09 | $0.00 | $131.32 |
| 2023 | $4.90 | $583.05 | $10,232.79 | $0.00 | $0.00 |
| 2024 | $3.34 | $48.81 | $0.00 | $0.00 | $120.53 |
AI valuation
Our deep-learning model estimates CollPlant Biotechnologies Ltd.'s (CLGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $48.81
- Current price
- $0.41
- AI upside
- +11,787.48%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.34
+226.35% upside
Graham-Dodd
—
— upside
Graham Formula
$120.53
+29,254.6% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CLGN | CollPlant Biotechnologies… | $0.41 | 7.18M | +11,787% | +226% | — | +29,255% | -2.30 | 2.84 | 74.26 | -1.89 | -1.72 | 2.87 | -417.09% | -3349.71% | -3225.05% | -79.46% | -364.64% | -62.87% | 0.23 | -1014.76 | 4.44 | 4.21 | 0.57 | 13387.00% | -9530.00% | 29214.00% | -38.11% | -4.75 | -308.10% | 0.00% | 0.00% | 0.00% | -1.71 | -2.02 | 57.12 | -6.47 |
| CVKD | Cadrenal Therapeutics, In… | $8.49 | 19.85M | — | — | — | — | -1.93 | 2.76 | — | -0.99 | — | 2.76 | 0.00% | — | — | -140.78% | 670.96% | -114.27% | 0.00 | — | 3.77 | 3.75 | 0.94 | -935.00% | — | 10840.00% | -35.84% | -2.74 | 450.80% | 0.00% | 0.00% | 7.97% | -0.96 | -1.43 | — | -1.66 |
| ENLV | Enlivex Therapeutics Ltd. | $1.15 | 27.95M | — | — | — | — | -1.63 | 1.03 | — | -0.09 | — | 1.03 | 0.00% | — | — | -55.95% | -720.93% | -46.54% | 0.02 | -1195.08 | 6.84 | 6.56 | 0.19 | -5321.00% | — | -4482.00% | -53.71% | -3.42 | -608.40% | 0.00% | 0.00% | 12.23% | -0.09 | -0.10 | — | -3.74 |
| KLTO | Klotho Neurosciences, Inc… | $0.53 | 28.02M | — | — | — | — | -0.90 | 4.69 | — | -1.00 | 0.00 | -4.99 | 0.00% | — | — | -700.07% | -323.09% | -264.53% | 0.23 | -15.54 | 0.13 | 0.05 | -0.04 | 4561429.00% | — | 56623.00% | -55.19% | -2.36 | -179.03% | 0.00% | 0.00% | 24.75% | -1.04 | -1.88 | — | -11.37 |
| MTVA | MetaVia Inc. | $1.51 | 3.32M | — | — | — | — | -0.44 | 1.52 | — | 0.13 | -0.97 | 1.52 | 0.00% | — | — | -224.18% | 426.89% | -141.35% | 0.02 | — | 1.94 | 1.94 | 0.55 | 4472.00% | — | 12784.00% | -205.58% | -2.99 | 366.27% | 0.00% | 0.00% | 0.00% | 0.13 | 0.16 | — | -16.10 |
| NRSN | NeuroSense Therapeutics L… | $0.91 | 22.42M | — | — | — | — | -2.06 | 8.14 | — | -1.79 | — | 8.14 | 0.00% | — | — | -2880.11% | 388.77% | -263.45% | 0.03 | -31.84 | 2.21 | 1.78 | 0.33 | -3373.00% | — | 2094.00% | -48.23% | -5.09 | 398.04% | 0.00% | 0.00% | 3.84% | -1.79 | -1.75 | — | -11.40 |
| RLYB | Rallybio Corporation | $7.54 | 39.81M | — | — | — | — | -0.56 | 0.53 | 50.94 | 0.55 | — | 0.53 | 100.00% | -9511.95% | -9084.12% | -68.85% | 1714.74% | -62.89% | 0.00 | — | 10.87 | 10.50 | 0.23 | -2772.00% | — | -1824.00% | -152.12% | -7.90 | 1396.88% | 0.00% | 0.00% | 0.00% | 0.54 | 0.67 | -51.82 | -4.85 |
| SONN | Sonnet BioTherapeutics Ho… | $1.26 | 8.43M | +87,488% | -33% | — | +67,885% | -0.19 | -2.83 | 73.88 | -0.12 | — | -2.83 | 100.00% | -63617.91% | -39929.30% | 2089.93% | 846.19% | -181.38% | -0.27 | — | 0.66 | 0.28 | 0.00 | -9218.00% | -8740.00% | -6049.00% | -625.56% | -2.68 | 614.69% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 72.88 | -73.78 |
| TAOX | TAO Synergies Inc. | $3.91 | 13.63M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -78.91% | 0.00% | -52.28% | 0.00 | — | 17.47 | 17.41 | 2.59 | -10000.00% | — | -564.00% | — | -4.82 | 63.45% | — | -7.40% | — | — | — | — | — |
| XCUR | Exicure, Inc. | $3.74 | 23.84M | — | +24% | — | — | -7.29 | 10.45 | 141.51 | -7.25 | — | 10.45 | 100.00% | -2446.40% | -1940.20% | -197.92% | -269.46% | -72.84% | 0.88 | -679.56 | 4.45 | 4.24 | 0.74 | -2464.00% | — | -7190.00% | -4.11% | -0.95 | -64.10% | 0.00% | 0.00% | 17.56% | -5.25 | -22.06 | 128.36 | -15.21 |
About CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
- CEO
- Yehiel Tal
- Employees
- 57
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.34 ÷ $0.41) − 1 = +226.35% (DCF, example).